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* Significant difference between baseline and drug infusions at P < 0,05 levels. MSAP:
mean systemic arterial pressure. MPAP: mean pulmonary arterial pressure. SVR: sys·
temic vascular resistance. PVR: pulmonary vascular resistance
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Conclusions: ETA receptor antagonists decrease pulmonary arterial pres-
sure in a beagle model and therefore may be clinically useful for therapy of
pulmonary hypertension.
in this model, U74389G attenuates the systolic and diastolic dysfunction of
myocardial stunning, most likely by protecting the lipid component of cell
membranes from peroxidation by oxygen-derived metabolites.
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The idealvasodilator for pulmonary hypertension (PH) would decrease pul-
monary arterial pressure with minimal systemic hypotension. The present
study was undertaken to investigate the pharmacologic effect of endothelin
receptor antagonists on cardiopulmonary hemodynamics in an animal model
of PH. We recently developed a beagle model of PH which allows accurate
determination of cardiopulmonary hemodynamics and which is associated
with elevated plasma endothelin-1 concentrations similar to PH in humans.
Twelve beagles (PH, n = 6; and Control, n = 6) were studied during base-
line conditions and during right atrial infusion of FR139317 (the ETA recep-
tor antagonist). RES-701-1 (the ETB receptor antagonist). nitroglycerin, and
prostaglandin E1. PH was induced in experimental animals 8 weeks after
an injection of 3 mglkg dehydromonocrotaline. The table showed hemody-
namic values of PH beagles at baseline and during drug infusion. FR139317
lowered pulmonary and systemic arterial pressure both in pulmonary hyper-
tensive and control animals, with a significantly greater effect on pulmonary
arterial pressure in pulmonary hypertensive animals. RES-701-1 increased
pulmonary arterial pressure only in PH. Nitroglycerin depressed pulmonary
and systemic arterial tone equally well in controls and animals with PH.
Prostaglandin El produced a greater decrease in systemic arterial pressure
in pulmonary hypertensive than in normal animals, despite same effect on
pulmonary arterial pressure in both.
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ACE Inhibition (Quinapril) Modulates Central
Vasopressin in the Rat
ABSTRACfS
Attenuation of Myocardial Stunning by a Novel
Nonglucocorticoid 21-Aminosteroid Inhibitor of
Lipid Peroxidation
(ns vs 0). Conclusion: 3D reconstruction can improve spatial appreciation of
the shape of thrombi and accurately measure their volumes. This approach,
suitable for epivascular or transvenous imaging, could potentially be used to
study thrombus formation and lysis in research and clinical studies.
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The beneficial effects of ACE inhibitors (ACE I) in heart failure and hyperten-
sion appear to be mediated not only by their influence on circulating ACE or
tissue ACE in the heart. Previous studies have also implicated the brain as
a possible site of actions for ACEI, e.g. by modifying central cardiovascular
mechanisms. Their effects on central vasopressin (AVP), which is an impor-
tant neurotransmitter in central cardiovascular regulation, are not known.
Following chronic administration of Quinapril (6 mglkgBW; 6 weeks,
p.o.) ACE activity (in vitro autoradiography using a specific ACE inhibitor
[1251]351A) was markedly inhibited in the thalamus (38%), hypothalamus
(37%). hypophysis (35%). cerebellum (36%) and plexus choroideus (20%)
suggesting Quinapril may cross the blood brain barrier after chronic treat-
ment. To study the influence of ACEI on central vasopressin, we deter-
mined the AVP content of 19 microdissected brain areas in rats treated with
Quinapril. Regarding the hypothalamic AVP-producing nuclei. increased AVP
levels could only been demonstrated in the paraventricular (PVN; Quinapril:
292 ± 197 vs. 2209 ± 568 pglmg protein of controls; p < 0.001). but not in the
supraoptic (SON) and the suprachiasmatic nucleus ISCN). Interestingly, vaso-
pressin synthesizing cells in the PVN project not only to the posterior pituitary
(like SON). but also to the lower brain stem and the spinal cord suggesting
an important role of the PVN in the regulation of the cardiovascular system.
Also, AVP content was sign. reduced in the median eminence (15643 ± 9240
vs. 28321 ± 4969, P < 0.001), where the hormone is mainly concentrated in
the hypothalamo-hypophysial tract. Furthermore, sign. changes were regis-
tered in the central amygdala, in the subcommissural organ and dorsal raphe
nucleus.
Conclusions: Autoradiographic study in vitro indicates that after chronic
treatment Quinapril is able to cross the blood brain barrier and suppress
central ACE activity. ACE inhibition with Quinapril markedly influences vaso-
pressin in important brain areas which are involved in central cardiovascular
regulation. Therefore, central modulatory effects of ACE inhibitor may con-
tribute to their overall therapeutic efficacy.
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There is a lack of data on gender difference in response to the newer an-
tihypertensive medicines. The Amlodipine Cardiovascular Community Trial
was designed to determine the blood pressure (BP) response of patient sub-
groups with mild-moderate hypertension to amlodipine besylate monother-
apy (5-1 0 mg/day). After a 2 week placebo phase, patients received amlodip-
ine for a 4 week efficacy/titration phase followed by a 12 week maintenance
phase. Goal BP was defined as a decrease in diastolic BP by 10 mmHg or
more plus a diastolic BP of less than 90 mmHg. Baseline systolic BP in mmHg
was 153 ± 16 and 155 ± 16 and diastolic BP 101 ± 4 and 100 ± 4 for males
In = 702) and females (n = 382), respectively. Decreases in BP at 4 weeks
were greater in females than males for both systolic (-19 vs -15 mmHg, p
< 0.0001) and diastolic BP (-14 vs -12 mmHg, p < 0.0001). Results were
maintained at 12 weeks. Ninety-one percent of females achieved goal BP
compared to 83% of men (p = 0.001). The greater response to amlodipine by
women remained significant after adjusting for: age, weight, dose (mglkg),
baseline BP. and drug compliance (99% in both women and men). There was
no difference in decrease in systolic and diastolic BP for women on hormone
replacement (-18 and -14 mmHg) versus those not on hormone replace-
ment (-19 and -14 mmHg). Thus, hormone replacement in women did not
account for the gender difference in BP response. Women reported edema
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Lipid peroxidation induced by oxygen free radicals has been implicated
in myocardial dysfunction during reperfusion. The effect of a new 21-
aminosteroid (Lazaroid, U74389G) that inhibits lipid peroxidation was stud-
ied in isolated, isovolumic rat hearts subjected to 20 min of normothermic
ischemia and subsequent repefusion for 30 min. Male Sprague-Dawley rats
(350-400 g) were randomized into three groups. Group 1 (Control; n = 13)
received vehicle before sacrifice and drug-free reperfusion, group 2 (Pretreat-
ment; n = 11) received 6 mglkg (iv) U74389G 30 min prior to sacrifice, and
group 3 (Reperfusion; n = 11) received 5 /LM U74389G in the reperfusion
solution. LV developed pressure (LVDP) and end-diastolic pressure ILVEDP)
were measured; maximum +dP/dt and the time constant of relaxation, Tau
(T). were calculated.
LVDP +dPldt LVEDP Tau
ImmHg) ImmHglsec) ImmHg) (msec)
Control group
Baseline 127 ± 6 2892 ± 127 5 ± 1 23 ± 1
30 min reperfusion 66 ± 5 1673 ± 140 30 ± 6 58 ±9
Pretreatment group
Baseline 122 ± 3 2893 ± 97 7 ± 1 24 ± 1
30 min reperfusion 112±3** 3171 ± 159** 14 ± 3* 28 ± 3*
Reperfusion group
Baseline 124 ± 4 2744 ± 77 5± 1 21 ± 1
30 min reperfusion 108 ± 5** 2785 ± 129** 14± 5* 32 ± 9*
*p < 0.05 VS. Control group, 30 min reperfusion; **p < 0.01 VS. Control group, 30 min
reperfusion
Conclusion: Whether administered before ischemia or during reperfusion
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Women Have a Higher Response Rate than Men
to the Antihypertensive Calcium Channel
Blocker Amlodipine
